2-(5-Bromo-2-phenylmethoxyphenyl)-2-methyl-1,3-dioxolane | 894099-87-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(5-Bromo-2-phenylmethoxyphenyl)-2-methyl-1,3-dioxolane
• CAS: 894099-87-7
• 化学式: C₁₇H₁₇BrO₃
• 分子量: 349.224
• InChiKey: JGPKFOCPOKPIJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(5-Bromo-2-phenylmethoxyphenyl)-2-methyl-1,3-dioxolane 在 三乙基硅烷 、 正丁基锂 、 三氟化硼乙醚 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 1-(2-(benzyloxy)-5-(α-D-fucofuranosyl))phenyl ethanone
  参考文献：
  名称：

  Stereoselective C-glycosidation of d-fucose derivatives directed by the protective groups

  摘要：

  Stereoselectivity in the C-glycosidation of lactones derived from D-fucose by following Kishi's method, which involves the addition of a nucleophile onto a carbohydrate-derived lactone and subsequent reduction of the lactol, was found to be reliant on the nature of the C2 and C3 protective groups. Lactones bearing TBDMS protecting groups selectively afford 1,3-trans products (alpha anomer), in which the stereoselective outcome is in apparent concordance with Woerpel's model. On the other hand, their benzylated congeners produce the 1,3-cis products (beta anomer) as the major diastereoisomers. The latter results suggest an abnormal behavior during the stereoselective nucleophilic substitution at the anomeric position of the benzylated lactones. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2014.04.005
• 作为产物：
  描述：

  溴甲苯 在 potassium carbonate 、 对甲苯磺酸 作用下， 以 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 7.25h， 生成 2-(5-Bromo-2-phenylmethoxyphenyl)-2-methyl-1,3-dioxolane
  参考文献：
  名称：

  Stereoselective C-glycosidation of d-fucose derivatives directed by the protective groups

  摘要：

  Stereoselectivity in the C-glycosidation of lactones derived from D-fucose by following Kishi's method, which involves the addition of a nucleophile onto a carbohydrate-derived lactone and subsequent reduction of the lactol, was found to be reliant on the nature of the C2 and C3 protective groups. Lactones bearing TBDMS protecting groups selectively afford 1,3-trans products (alpha anomer), in which the stereoselective outcome is in apparent concordance with Woerpel's model. On the other hand, their benzylated congeners produce the 1,3-cis products (beta anomer) as the major diastereoisomers. The latter results suggest an abnormal behavior during the stereoselective nucleophilic substitution at the anomeric position of the benzylated lactones. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2014.04.005

文献信息

• [EN] NOVEL 3-(2-AMINO-6-PYRIDINYL)-4-HYDROXYPHENYL AMINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE 3-(2-AMINO-6-PYRIDINYL)-4-HYDROXYPHÉNYLAMINE
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2006068410A1

  公开（公告）日：2006-06-29

  [EN] The present invention relates to novel compounds having 3-(2-amino-6-pyrimidinyl)-4-hydroxyphenyl amine structure, as being illustrated in Formula 1, and preparations for preparation of them, and the use of them, and pharmaceutical compositions containing them at a therapeutically effective amount. The compounds according to the present invention are useful for the treatment and prevention of diseases resulting from the undesired KDR activity, for example, angiogenesis-related diseases such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy, etc.
  [FR] La présente invention concerne de nouveaux composés de structure 3-(2-amino-6-pyrimidinyl)-4-hydroxyphénylamine, tels qu'illustrés par la Formule 1, ainsi que leurs méthodes de synthèse, leurs applications, et des préparations pharmaceutiques contenant lesdits composés à des teneurs thérapeutiques. Les composés selon la présente invention peuvent être employés dans le traitement prophylactique et thérapeutique de maladies dues à une activité anormale de KDR, par exemple des maladies de type angiogenèse telles que les cancers, le psoriasis, la polyarthrite rhumatoïde, la rétinopathie diabétique, etc.